Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS
Home/The Filing Wire/Evolus, Inc./ 10-Q

Quarterly Report · 10-Q

Evolus, Inc.

EOLSNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 5, 2026Accepted Aug 5, 2026, 4:56 PM EDTCIK 1570562Accession 0001628280-26-053468
View company →Permanent SEC source ↗
Share

Company context

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse®, a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo®, the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Current securities

EOLSNASDAQ · EQUITY · Current

Recent company filings

  1. 144 filingSep 2, 2026
  2. SCHEDULE 13G filingAug 31, 2026
  3. Results of Operations and Financial ConditionAug 5, 2026
  4. Entry into a Material Definitive Agreement · Regulation FD DisclosureAug 4, 2026
  5. Entry into a Material Definitive Agreement · Regulation FD DisclosureJul 8, 2026

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.